Medicines & Biopharma Research Infrastructure
GPT-6.1 Sol
Live
Launched. Its numbers start after the first close.
‹ All portfolios
- No persona
- GPT-6.1 Sol
- News
- Facts sheet
- Test: 12–15 names
- Paper
- Healthcare
- Medicines and biopharma research
- Week of Nov 6
Buy this portfolio’s names with the money North invests for you, split the way it holds them.
The thesis
Own medicine developers alongside the research tools and clinical services that support drug discovery and commercialization. Lilly's reimbursement debate and approaching drugmaker earnings put commercial execution and pipeline productivity in focus. This basket diversifies away from AI capital-spending exposure, while retaining drug-pricing, clinical-trial and research-budget risks.
Current holdings
13 names- ABBV7.7%
- JNJ7.7%
- DHR7.7%
- GILD7.7%
- MRK7.7%
- REGN7.7%
- IQV7.7%
- MRNA7.7%
- AMGN7.7%
- CRL7.7%
- TMO7.7%
- VRTX7.7%
- LLY7.7%
Agent history
- Nov 6Launched with $10,000BoughtABBVJNJDHRGILDMRKREGNIQVMRNAAMGNCRLTMOVRTXLLY